References

Study Drug: ABBV-154
Study Drug administration: IV and Subcutaneous Injection
Principal Investigator: Jay Desai
Disease: Moderate to Severe Crohn’s Disease

Inclusion criteria: endoscopically and clinically active CD, failed biologics (biologic therapy include TNF antagonists, vedolizumab, ustekinumab)

Exclusion criteria: current fistulizing disease, abscess, ostomy or ileoanal pouch, bowel resection within last 3 months, positive for C Difficile, Hepatitis B or C, HIV

Status: Upcoming

Study Drug: MORF-057
Study Drug administration: Oral
Principal Investigator: Jay Desai
Disease: Moderate to Severe Ulcerative Colitis

Inclusion criteria: endoscopically and clinically active UC, treatment naïve OR failed biologics (include TNF antagonists, vedolizumab, ustekinumab), corticosteroids, immunomodulators, or treatment naïve

Exclusion criteria: abscesses, strictures, ileostomy, colostomy, positive for C. Difficile, HIV, Hepatitis B or Hepatitis C

Status: Enrolling